Cardiology in reviewJun 20, 2025

Heart and blood vessel benefits of drugs that activate GLP-1 receptors

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 20, 2026

Abstract

GLP-1 receptor agonists (GLP-1 RAs) are associated with significant reductions in major adverse cardiovascular events in patients with type 2 diabetes.

GLP-1 RAs were initially approved for improving glycemic control in type 2 diabetes but also lead to weight loss.
Their use has expanded to include treatment for obesity in overweight patients, regardless of diabetes status.
Multiple cardiovascular outcome trials indicate that GLP-1 RAs significantly reduce cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.
Potential mechanisms for cardiovascular benefits include improved glycemic control, weight loss, modest blood pressure reduction, and anti-inflammatory effects.
Investigation into the role of GLP-1 RAs for treating heart failure is ongoing, but early trials have shown inconsistent results.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially approved by the Food and Drug Administration to improve glycemic control in patients with type 2 diabetes (T2DM). However, their use was associated with a significant weight loss benefit, subsequently leading to their Food and Drug Administration approval for use in obesity and select overweight patients with or without T2DM. Additionally, as part of regulatory clinical trials required for approval of all antidiabetic medications, GLP-1 RAs were discovered to have significant cardiovascular benefits beyond their glycemic control and weight loss properties. Multiple cardiovascular outcome trials demonstrated that GLP-1 RAs cause a significant reduction in major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, in patients with T2DM. The proposed mechanisms of action responsible for GLP-1 RAs cardiovascular benefits include their improvement in glycemic control, substantial weight loss effect, modest reduction in blood pressure, antiatherosclerotic effect, and anti-inflammatory effect. Additionally, with the increase in the heart failure (HF) epidemic worldwide, researchers have begun investigating whether GLP-1 RAs may have a role in the treatment of HF with reduced or preserved ejection fraction in patients with or without T2DM. However, early, small, underpowered clinical trials on this topic have yielded varying results and were unable to clearly identify the role of GLP-1 RAs in the treatment of HF. There is a growing need for a large clinical trial to investigate and establish the safety and efficacy of GLP-1 RAs in HF patients with and without T2DM.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Disclosure: The authors declare no conflict of interest.

PubMed

Heart and blood vessel benefits of drugs that activate GLP-1 receptors

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief